Sillajen stock surges upon clinical trial announcement for Pexa-Vec

Sillajen stock surges upon clinical trial announcement for Pexa-Vec

Sillajen is a former resident of the Mission Bay Innovation Center.

Dow AgroSciences and TeselaGen Expanding Advanced Biodesign Platform for Ag

Dow AgroSciences and TeselaGen Expanding Advanced Biodesign Platform for Ag

TeselaGen and Dow collaborate on a state-of-the-art biological design automation platform

Magnamosis, a New Magnetic Way to Connect Intestines, Proving Itself in Clinical Trial

Magnamosis, a New Magnetic Way to Connect Intestines, Proving Itself in Clinical Trial

The so-called "Harrison rings" were used on five patients.

Channel Medsystems® Secures $14.1M Financing

Channel Medsystems® Secures $14.1M Financing

Channel Medsystems has developed the Cerene® Cryotherapy Device to treat heavy menstrual bleeding.

Big Pharma ally Atreca scoops $35M as I-O assets near IND

Big Pharma ally Atreca scoops $35M as I-O assets near IND

Atreca was an early portfolio company of QB3-affiliated Mission Bay Capital.

JLABS resident Meissa Vaccines nabs new seed capital to advance RSV vaccine

JLABS resident Meissa Vaccines nabs new seed capital to advance RSV vaccine

Meissa was incorporated through QB3 Startup in a Box.

4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

The partnership will develop intravitreal gene therapeutics for patients using 4DMT-proprietary AAV vectors.

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

eFFECTOR, in Mission Bay Capital's portfolio, is a leader in the development of selective translation regulators for the treatment of cancer.

Grifols acquires minority stake in GigaGen

Grifols acquires minority stake in GigaGen

Grifols, based in Spain, is set to acquire a 44% stake in GigaGen, a startup that discovers and develops pre-clinical biotherapeutics.

A new breed of scientist, with brains of silicon

A new breed of scientist, with brains of silicon

Science Magazine profiles Zymergen's AI/robotics technology for microbe engineering.